Axsome Therapeutics is trading 11.31% lower at $128.09 after third-quarter results beat analyst estimates; the decline appears tied to continued high commercialization spending and expectations for slightly higher Q4 gross-to-net discounts.
- Revenue was $259.7 million, up 52% year over year, and the loss narrowed to $0.25 per share.
- The company did not provide formal revenue guidance.
- Current trading volume was not reported, leaving activity versus normal levels unclear.